Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

NCT06219239 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Transfusion-dependent Beta-Thalassemia

Interventions

GENETIC: KL003 cell injection Drug Product

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

[object Object]